LIVEDIFF, NCT06306014: Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients |
|
|
| Recruiting | 1/2 | 56 | Europe | EXL01, Placebo | Hospices Civils de Lyon, Exeliom Biosciences | Clostridioides Difficile Infection, Recurrent Infection | 01/27 | 01/27 | | |